

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1430 Alexandria, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,066	10/24/2006	Ulrike Wachendorff-Neumann	2400.0230000/VLC/CMB	6965
26111 STERNE KES	7590 12/30/200 SSLER GOLDSTEIN	EXAM	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			PIHONAK, SARAH	
			ART UNIT	PAPER NUMBER
		1627	•	
			MAIL DATE	DELIVERY MODE
			12/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/573,066 WACHENDORFF-NEUMANN ET Office Action Summary Examiner Art Unit SARAH PIHONAK 1627 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 16 September 2009. 2a) ☐ This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 4,13 and 14 is/are pending in the application. 4a) Of the above claim(s) 13 and 14 is/are withdrawn from consideration. Claim(s) is/are allowed. 6) Claim(s) 4 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.

Ap	plicati	on P	apers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. §	119(a)-(d) or (f).
a)⊠ All b)□ Some * c)□ None of:	

Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attaciment(s)	
Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date
3) Information Disclosure Statement(s) (PTO/SB/08)	 Notice of Informal Patent Application
Paper No(s)/Mail Date	6) Other: .

Application/Control Number: 10/573,066 Page 2

Art Unit: 1627

DETAILED ACTION

This application is a national stage entry of PCT/EP04/10830, filed on 9/28/2004.

Priority

This application claims foreign priority to Application No. 103-47-090.5, filed on 10/10/2003.

Request for Continued Examination

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/16/2009 has been entered.

Response to Remarks

2. Applicant's arguments filed 9/16/2009 have been considered but they are not fully persuasive. In the office action dated 6/16/2009, claims 4 and 15-16 were rejected under 35 USC § 103(a) as being unpatentable over Bruns et. al., US PG Publication No. 2002/0198222, in view of Dunkel et. al., DE 10215292 patent application. The Applicants have argued that Bruns et. al. teaches pesticide compounds which are not carboxamides, and that Dunkel teaches pyrazolyl carboxamide derivatives; as these pesticides are of different classes of compounds, one of ordinary skill in the art would not have been motivated to substitute the compounds taught by Dunkel for the pesticide compounds taught by Bruns. Additionally, the Applicants have amended the claims to

Art Unit: 1627

be drawn to a synergistic composition comprising the carboxamide N-(3',4'-dichloro-5fluoro-1.1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and at least one triazole compound, in a ratio of 50:1 to 1:50 of carboxamide to triazole. While the Applicant's amendment has been considered, it is not commensurate in scope with the support provided by the specification. It is noted that on p. 70, Table 21 of the specification, the Applicants have stated that the preferred mixing ratio for carboxamides and triazoles is between 50:1 to 1:50. However, for the results which demonstrate synergy, the only observed ratio between N-(3',4'-dichloro-5-fluoro-1,1biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and propiconazole, epoxiconazole, prothioconazole, tebuconazole, and bitertanol is 1:1 (p. 19, Table A; p. 80, Table B; p. 83, Table D; p. 86, Table E). Therefore, as the specification shows only the synergistic results of a 1:1 ratio between N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and the claimed triazole compounds, and presents no other data of different weight ratios between the claimed range of 50:1 to 1:50, the claims are not fully supported by the specification. In further consideration of the amended claims, the rejection under 35 USC § 103(a) in view of Bruns et. al. and Dunkel et. al. is withdrawn; however, a new art rejection has been made, which will be discussed in detail further in this office action. However, it is noted that if the Applicants were to amend the claims to reflect the weight ratio of N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1Hpyrazole-4-carboxamide and propiconazole, epoxiconazole, prothioconazole, tebuconazole, and bitertanol as supported by the specification, or to provide additional

Application/Control Number: 10/573,066 Page 4

Art Unit: 1627

data to support the currently amended claims, such amendments would be considered by the examiner.

Claims 15-16 have been cancelled by the Applicants. Claims 13-14 were previously withdrawn due to the restriction requirement. In the event that claim 4 is found allowable, a rejoinder of the method claims with claim 4 will be considered.

- Claim 4 was examined.
- 4. Claim 4 was rejected.

Claim Rejections-35 USC § 103

- The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary sikil in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - Resolving the level of ordinary skill in the pertinent art.
 - Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein

Application/Control Number: 10/573,066

Art Unit: 1627

were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dunkel et.
 al., DE 10215292 patent application. For convenience, the English language equivalent of DE 10215292, CA Patent Application No. 2476462, will be referenced in this office action.

Claim 4 is drawn to a synergistic composition comprised of the compound N(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4carboxamide, and at least one triazole selected from propiconazole, epoxiconazole,
prothioconazole, tebuconazole, or bitertanol, in a ratio of 50:1 to 1:50 of carboxamide to
triazole

Dunkel et. al. teaches carboxamide compounds as pesticidal agents effective for crop protection (Abstract; p. 1, lines 4-6, and lines 13-22; p. 20, lines 25-27). Dunkel et. al. teaches the claimed carboxamide compound, N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (p. 52, Table C, compound 11). Dunkel et. al. teaches the formulation of N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide with carriers, extenders, and solvents (p. 25, line 7-p. 26, line 2). Additionally, Dunkel et. al. teaches that N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-

Application/Control Number: 10/573,066

Art Unit: 1627

pyrazole-4-carboxamide can be combined in a mixture with other known fungicides or insecticides, and, in many cases, a synergistic effect is observed (p. 26, lines 18-23). Particularly, it is taught that the combination of N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide with other known insecticides or fungicides can broaden crop protection and prevent the development of resistance (p. 26, lines 18-23). Dunkel et. al. teaches that suitable fungicides to be mixed together with N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide include bitertanol (p. 26, lines 25 and 32), epoxiconazole (p. 27, line 10), prothioconazole (p. 27, lines 31-32), propiconazole (p. 27, line 31), and tebuconazole (p. 28, line 4).

Dunkel et. al. teaches that N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide is an effective agent for
protecting crops from many different microorganisms, and that N-(3',4'-dichloro-5-fluoro1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide can be mixed
together with other fungicidal agents such as propiconazole, epoxiconazole,
prothioconazole, tebuconazole, and bitertanol to provide a synergistic effect. As such, it
would have been prima facie obvious to one of ordinary skill in the art, at the time of the
invention, to combine N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1methyl-1H-pyrazole-4-carboxamide with the claimed triazoles to obtain a synergistic
composition to protect crops from pests, fungi, and many other microorganisms. Dunkel
et. al. does not explicitly teach that N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide is combined with the claimed

Application/Control Number: 10/573,066

Art Unit: 1627

triazole compounds in a ratio from 50:1 to 1:50; however, it would have been considered routine for one of ordinary skill in the art to determine optimum weight ratio ranges of N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide to triazole compounds for an enhanced pesticidal and fungicidal effect. As the development of optimum working ranges would have been considered routine to one of ordinary skill in the art, it would have been prima facie obvious, at the time of the invention, to establish a weight ratio range of N-(3',4'-dichloro-5-fluoro-1,1-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide to triazole compounds between 50:1 and 1:50.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-every other Friday 8:00 AM - 5:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/573,066 Page 8

Art Unit: 1627

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S.P.

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1627